Intellia Therapeutics Inc (NTLA) Net Margin

Symbol and logo of brand Intellia Therapeutics (NTLA)

Leadership in CRISPR technologies and patent protection support the quotes of Intellia Therapeutics (NTLA), as confirmed by sales margin dynamics. However, the lack of commercial products and reliance on equity offerings create financial volatility. Experienced management is systematically steering development toward approval. The value of -805.80 determines this parameter level, allowing for a comparison of current profitability with historical data to assess the market trend.

Intellia Therapeutics (NTLA) - Net Sales Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns for Intellia Therapeutics

- share price and expert price forecast:
Initial company analysis:Intellia Therapeutics, NTLA
Flagship merchandise of Intellia Corp

The monopoly status of Intellia Therapeutics (NTLA), secured by CRISPR/Cas9 patents and high FDA regulatory barriers, determines the future profitability of the business. By analyzing the net profit margin, an investor assesses the portion of profit in every dollar of revenue after deducting all operating expenses and taxes. Positive dynamics in this metric confirm the effective capitalization of intellectual property and the real cash return on innovation.

Competitor analysis for Intellia Therapeutics

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Net Margin Stoke Therapeutics Inc|BLFS: Net Profit Rate|Return on Sales by Net Profit WVE (Wave Life Sciences Corp)|Company Sales Margin Maze Therapeutics Corp|Sionna Therapeutics Inc - Return on Sales by Net Profit|PRME (primemedicine.com) - Net Profit Margin|TSHA - Net Margin|QURE (uniQure) - Net Return on Sales|MeiraGTx Corp (MGTX) - Net Margin|Regenxbio - Net Profit Rate|Net Margin solidbio.com|Net Margin ocugen.com OCGN|Net Sales Margin PACB|Benitec - Net Return on Sales|Net Margin Design Therapeutics DSGN|Net Sales Margin Rocket Pharmaceuticals RCKT|Net Profit Margin 4D Molecular Corp|LXEO: Net Margin|KRRO (Korro Bio, Inc) - Return on Sales by Net Profit|Editas Medicine (EDIT) - Net Sales Margin|Net Margin Silence Therapeutics Inc.|Net Return on Sales PRQR (proqr.com)|Net Margin Codexis Bio (CDXS)|Net Sales Margin sangamo.com (SGMO)|Net Margin nautilus.bio NAUT|Company Sales Margin Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Net Sales Margin|GBIO - Net Sales Margin|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX